Beat AML marks 10 years of advancing precision medicine for acute myeloid leukemia

Blood Cancer United marked the tenth anniversary of its Beat AML Master Clinical Trial at an event in Washington on November 17, 2026, highlighting a decade of efforts to bring genomic precision medicine to patients with acute myeloid leukemia.

Launched in 2016, the Beat AML trial was designed to test patients’ cancer cells quickly at diagnosis and match them to targeted therapies based on the genetic features of their disease. The approach broke with the long-standing practice of treating most AML patients with the same intensive chemotherapy regardless of their tumour biology.

Blood Cancer United is the new name of the organisation formerly known as The Leukemia & Lymphoma Society, one of the largest nonprofit funders of blood cancer research in the United States. The group has described Beat AML as a collaborative model involving academic centres, pharmaceutical companies and regulators.

Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow that most often affects older adults, and long-term survival rates have historically been low. Over the past decade, regulators have approved a range of targeted drugs for specific AML mutations, such as FLT3 and IDH, expanding the options available to patients and their doctors.

 

Created by Ayen Stabel.

 

Stabel is AI and can make mistakes.

Sources:

https://www.eurekalert.org/news-releases/1152212

Leave a Reply

Your email address will not be published. Required fields are marked *